

## **Tirzepatide (Mounjaro®) use for weight loss**

### **BNSSG ICS update – April 2025**

NHS England have now published Interim Commissioning Guidance on the [Implementation of NICE TA1026 and the NICE funding variation for tirzepatide \(Mounjaro®\) for the management of obesity](#). This includes the detail of the eligible patient cohorts, prioritisation strategy and phased implementation.

From 1<sup>st</sup> April 2025, Tier 3 Specialist Weight Management Services (SWMS) will be able to assess patients for eligibility for tirzepatide in line with [NICE TA1026](#) criteria. Information on access to Tier 3 and 4 weight management services is available on Remedy [here](#).

From the end of June 2025, primary care-based services will be established to assess and offer tirzepatide to eligible patients, in line with NHSE agreed priority cohorts. We continue to work with our system partners in BNSSG to develop these community-based services that will allow patients to access tirzepatide, alongside the ‘wraparound care’ element required by NICE guidance, in primary care. Wraparound care focuses on diet, nutrition and increasing physical activity and may include programmes delivered digitally and/or in person. **We remind practices not to prescribe tirzepatide for weight loss yet.**

A series of FAQs, originally published in February have been updated: Healthcare Professionals [here](#) and for patients [here](#).